E-mail us:
service@prospectnews.com
Or call: 212 374 2800
Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
Add to balance / Manage account
Not logged in
Prospect News home
>
Main news index
>
All issuers starting with A
>
Issuers starting with A, HY only
>
All stories on Advanz Pharma Holding Ltd.
>
Stories on Advanz Pharma Holding Ltd., HY only
Search again
Enter part or all of the issuer name:
Market:
All markets
No structured products
Bank loans
Canadian bonds
CLOs
Convertibles
Distressed debt
Emerging markets
High yield
Investment grade
Liability management
Municipals
PIPEs
Preferreds
Private placements
All leveraged markets
Structured products
Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each.
All others are $1.00 each. Headlines in
gray
are not currently covered by your subscription.
Advanz Pharma Holding Ltd.
4/1/2025
HY
New Issue: Advanz Pharma sells 6.5-year secured notes in €615 million, £250 million tranches
4/1/2025
HY
Market Commentary:
Morning Commentary: Junk slips in mixed trading; Advanz Pharma euro/sterling notes on deck
4/1/2025
HY
Advanz Pharma launches €615 million and £300 million 6.5-year senior secured notes
3/28/2025
HY
Advanz Pharma starts roadshow for €615 million and £300 million secured notes
©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.
